Medical cannabis is associated with a number of favorable outcomes for patients with rheumatic diseases, including a lessened symptom burden and discontinuation of opioids or sleeping pills.
A team, led by Kevin Boehnke, PhD, University of Michigan, characterized medical cannabis use among patients with rheumatologic disease in the US and Canada, looking at demographic and clinical differences between those with inflammatory compared to non-inflammatory rheumatic conditions.
The data was presented during the American College of Rheumatology (ACR) Convergence 2022.
– Read the entire article at HCP Live.
